• Login
    View Item 
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    •   Home
    • The Christie Research Publications Repository
    • All Christie Publications
    • View Item
    JavaScript is disabled for your browser. Some features of this site may not work without it.

    Browse

    All of ChristieCommunitiesTitleAuthorsIssue DateSubmit DateSubjectsThis CollectionTitleAuthorsIssue DateSubmit DateSubjectsProfilesView

    My Account

    LoginRegister

    Local Links

    The Christie WebsiteChristie Library and Knowledge Service

    Statistics

    Display statistics

    Corrigendum to pembrolizumab plus axitinib versus sunitinib as first-line treatment of advanced renal cell carcinoma: 43-month follow-up of the phase 3 KEYNOTE-426 study

    • CSV
    • RefMan
    • EndNote
    • BibTex
    • RefWorks
    Thumbnail
    Name:
    Plimack, Powles - Corrigendum.pdf
    Size:
    315.2Kb
    Format:
    PDF
    Description:
    Found with Open Access Button
    Download
    Authors
    Plimack, ER
    Powles, T
    Stus, V
    Gafanov, R
    Nosov, D
    Waddell, Tom
    Alekseev, B
    Poulioti, F
    Melichar, B
    Soulieres, D
    Borchiellini, D
    McDermott, RS
    Vynnychenko, I
    Chang, YH
    Tamada, S
    Atkins, MB
    Li, CX
    Perini, R
    Molife, LR
    Bedke, J
    Riniu, BI
    Show allShow less
    Affiliation
    The Christie NHS Foundation Trust, Manchester, UK.
    Issue Date
    2023
    
    Metadata
    Show full item record
    Citation
    Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, et al. Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study ( vol 84 , pg , 449 , 2023). EUROPEAN UROLOGY. 2023 NOV;84(5):E123-E4. PubMed PMID: WOS:001092250500001. English.
    Journal
    European Urology
    URI
    http://hdl.handle.net/10541/626751
    DOI
    10.1016/j.eururo.2023.08.010
    PubMed ID
    37666734
    Additional Links
    https://dx.doi.org/10.1016/j.eururo.2023.08.010
    Type
    Other
    Language
    en
    ae974a485f413a2113503eed53cd6c53
    10.1016/j.eururo.2023.08.010
    Scopus Count
    Collections
    All Christie Publications

    entitlement

    Related articles

    • Corrigendum to "Pembrolizumab Plus Axitinib Versus Sunitinib as First-line Treatment of Advanced Renal Cell Carcinoma: 43-month Follow-up of the Phase 3 KEYNOTE-426 Study" [Eur Urol 84(5) (2023) 449-454].
    • Authors: Plimack ER, Powles T, Stus V, Gafanov R, Nosov D, Waddell T, Alekseev B, Pouliot F, Melichar B, Soulières D, Borchiellini D, McDermott RS, Vynnychenko I, Chang YH, Tamada S, Atkins MB, Li C, Perini R, Molife LR, Bedke J, Rini BI
    • Issue date: 2024 Feb
    • Pembrolizumab plus axitinib versus sunitinib monotherapy as first-line treatment of advanced renal cell carcinoma (KEYNOTE-426): extended follow-up from a randomised, open-label, phase 3 trial.
    • Authors: Powles T, Plimack ER, Soulières D, Waddell T, Stus V, Gafanov R, Nosov D, Pouliot F, Melichar B, Vynnychenko I, Azevedo SJ, Borchiellini D, McDermott RS, Bedke J, Tamada S, Yin L, Chen M, Molife LR, Atkins MB, Rini BI
    • Issue date: 2020 Dec
    • Cost-Effectiveness of Pembrolizumab plus Axitinib Versus Sunitinib as First-Line Therapy in Advanced Renal Cell Carcinoma in the U.S.
    • Authors: Ding D, Hu H, Shi Y, She L, Yao L, Zhu Y, Zeng S, Shen L, Huang J
    • Issue date: 2021 Feb
    • Re: Jens Bedke, Brian I. Rini, Elizabeth R. Plimack, et al. Health-related Quality of Life Analysis from KEYNOTE-426: Pembrolizumab plus Axitinib Versus Sunitinib for Advanced Renal Cell Carcinoma. Eur Urol. 2022;82:427-39.
    • Authors: Zhao B
    • Issue date: 2022 Dec
    • Pembrolizumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma.
    • Authors: Rini BI, Plimack ER, Stus V, Gafanov R, Hawkins R, Nosov D, Pouliot F, Alekseev B, Soulières D, Melichar B, Vynnychenko I, Kryzhanivska A, Bondarenko I, Azevedo SJ, Borchiellini D, Szczylik C, Markus M, McDermott RS, Bedke J, Tartas S, Chang YH, Tamada S, Shou Q, Perini RF, Chen M, Atkins MB, Powles T, KEYNOTE-426 Investigators
    • Issue date: 2019 Mar 21
    DSpace software (copyright © 2002 - 2025)  DuraSpace
    Quick Guide | Contact Us
    Open Repository is a service operated by 
    Atmire NV
     

    Export search results

    The export option will allow you to export the current search results of the entered query to a file. Different formats are available for download. To export the items, click on the button corresponding with the preferred download format.

    By default, clicking on the export buttons will result in a download of the allowed maximum amount of items.

    To select a subset of the search results, click "Selective Export" button and make a selection of the items you want to export. The amount of items that can be exported at once is similarly restricted as the full export.

    After making a selection, click one of the export format buttons. The amount of items that will be exported is indicated in the bubble next to export format.